John J Orloff

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. doi request reprint The future of drug development: advancing clinical trial design
    John Orloff
    Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936, USA
    Nat Rev Drug Discov 8:949-57. 2009
  2. doi request reprint Innovative approaches to clinical development and trial design
    John J Orloff
    Novartis Pharma AG, One Health Plaza, East Hanover, NJ 07936 1080, USA
    Ann Ist Super Sanita 47:8-13. 2011
  3. doi request reprint Communicating with the FDA: the "third rail" of a new model for drug development
    Donald R Stanski
    Global Head Modeling and Simulation, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936 1080, USA
    J Clin Pharmacol 48:144-5. 2008
  4. ncbi request reprint Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis
    Patrice Matchaba
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    Clin Ther 27:1196-214. 2005

Detail Information

Publications4

  1. doi request reprint The future of drug development: advancing clinical trial design
    John Orloff
    Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936, USA
    Nat Rev Drug Discov 8:949-57. 2009
    ..Applications and examples of the use of these tools--such as Bayesian methodologies--in early- and late-stage drug development are discussed, as well as the advantages, challenges and barriers to their more widespread implementation...
  2. doi request reprint Innovative approaches to clinical development and trial design
    John J Orloff
    Novartis Pharma AG, One Health Plaza, East Hanover, NJ 07936 1080, USA
    Ann Ist Super Sanita 47:8-13. 2011
    ..Greater awareness of the distinct advantages of innovative designs by regulators and sponsors are crucial to increasing the adoption of these modern tools...
  3. doi request reprint Communicating with the FDA: the "third rail" of a new model for drug development
    Donald R Stanski
    Global Head Modeling and Simulation, Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936 1080, USA
    J Clin Pharmacol 48:144-5. 2008
  4. ncbi request reprint Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis
    Patrice Matchaba
    Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
    Clin Ther 27:1196-214. 2005
    ..The cardiovascular (CV) safety of non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors has been the subject of considerable debate...